Nucleix Ltd. develops, manufactures and markets innovative non-invasive molecular cancer diagnostic tests. Our highly sensitive and specific tests are based on identification of subtle changes in methylation patterns. Nucleix technology is based on a combination of a new biochemical platform in conjunction with sophisticated algorithms.

Our first product – Bladder EpiCheck  is a urine test for monitoring of bladder cancer. This test has shown very high sensitivity and specificity, and it is expected to reach the market in Q3 2016.

Nucleix pipeline includes diagnostic tests for lung and colorectal cancer detection from blood samples, using its proprietary and highly innovative technology.

Nucleix is backed up by leading investors including OrbiMed – one of the world’s largest bio-medical VC funds.

NUCLEIX AT A GLANCE

dna

International expertise of diagnostic tests based on DNA methylation analysis

dna

Our employees: 75% Masters Degree and above, 30% MD or PhD

dna

Backed by OrbiMed and other leading investors

dna

Started R&D in 2008

dna

5 Patents submitted worldwide

dna

First Product-Bladder EpiCheck